The following trials provide information to treat various types of disease of the brain and the central and local nervous systems, both for ongoing and completed clinical trials. For more information on this therapy area please click here.
- collapse Observational Study on Costs and Caregiver Burden in Alzheimer's Disease
- collapse Pt. A: Ph I, Sngl-Blind, Randomized, Pcbo-Controlled 3-Way Crossover Study followed by an Open-label Food Effect Study to Assess the PK of IV and Oral AZD6765 in Healthy Male and Female Subjects Pt.B: Ph I, Double-Blind, Randomized, Placebo-Controlled Study to Assess the safety, tolerability and PK of AZD6765 When Administered in Multiple Ascending Doses to Healthy Subjects
- collapse A Phase I, Single-center, Randomized, Double-blind, Placebo-controlled Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6765 in Healthy Male and Female Japanese and Caucasian Subjects
- collapse A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjuntive AZD6765 in Subjects with Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
- collapse A Phase IIa, Multi-Center, Randomized, Double-blind, Placebo-controlled, Parallel-Group Study to Assess the Antidepressant Effect and Onset of Effect of AZD6765 in Treatment-Resistant Major Depressive Disorder Patients.
- collapse An Open Label Positron Emission Tomography (PET) Study Using 2-[18F]-F-A85380 to Determine ?4?2 Neuronal Nicotinic Receptor Occupancy of AZD3480 After Oral Administration to Healthy Male Subjects (Non Nicotine Users)
- collapse A phase I, double blind, randomised, two-way cross over, single- centre study in healthy CYP2D6 extensive metabolisers and poor metabolisers to investigate the potential of AZD3480 to inhibit cytochrome P450 1A2, 2C19, 3A4, 2C8, 2B6 and UGT1A1 activity
- collapse A Multi-Center Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase IIb Proof of Concept Study with 3 Oral Groups of AZD3480 during 12 Weeks Treatment of Cognitive Deficits in Patients with Schizophrenia
- collapse A multi-center, double-blind, double-dummy, placebo controlled, parallel group, randomized, phase IIb proof of concept study with 3 oral dose groups of AZD3480 or donepezil during 12 weeks treatment in patient with Alzheimer's disease.
- collapse A Double-blind, Randomised, Multicentr, Placebo-controlled, 4-Ways Crossover Study to Investigate the Effect on the QT/QTc interval of Repeated and Escalating Doses of AZD3480 during 6 Days, using Moxifloxacin as a Positive Control, in Healthy Male Volunteers, CYP2D6 Extensive and Poor Metabolisers.
